Paper · 32017145
Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
Ahn JC and 6 others. Hepatology, 2021. Cited by 278 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Papers, record 32017145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32017145
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Neoplastic Cells, Circulating | Major topic |
| Epithelial Cell Adhesion Molecule | |
| Humans | |
| Liquid Biopsy | |
| Prognosis |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA172086 | NCI NIH HHS | United States | R01CA172086 | PubMed and NIH | NIH RePORTER |
| R21 CA235340 | NCI NIH HHS | United States | R21CA235340 | PubMed and NIH | NIH RePORTER |
| P01 CA233452 | NCI NIH HHS | United States | P01CA233452 | PubMed and NIH | NIH RePORTER |
| R01 CA253651 | NCI NIH HHS | United States | R01CA253651 | PubMed and NIH | NIH RePORTER |
| R01 CA246304 | NCI NIH HHS | United States | R01CA246304 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05242237 | Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform | Results |
Source ClinicalTrials.gov
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References94
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,521,467 | Dual-Selective and Dual-Enhanced SERS Nanoprobes Strategy for Circulating Hepatocellular Carcinoma Cells Detection. | Chemistry | 2018 | https://conductscience.org/library/papers/29521467 | PubMed |
| 2 | 14,999,698 | Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. | Hepatology | 2004 | https://conductscience.org/library/papers/14999698 | PubMed |
| 3 | 21,527,564 | Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21527564 | PubMed |
| 4 | 28,883,691 | Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/28883691 | PubMed |
| 5 | 27,706,479 | Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein. | JAMA Surg | 2017 | https://conductscience.org/library/papers/27706479 | PubMed |
| 6 | 30,176,913 | Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/30176913 | PubMed |
| 7 | 24,923,562 | Circulating biomarkers in hepatocellular carcinoma. | Cancer Chemother Pharmacol | 2014 | https://conductscience.org/library/papers/24923562 | PubMed |
| 8 | 27,662,377 | Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay. | Cancer Biol Ther | 2016 | https://conductscience.org/library/papers/27662377 | PubMed |
| 9 | 25,171,411 | Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. | Cell | 2014 | https://conductscience.org/library/papers/25171411 | PubMed |
| 10 | 25,984,697 | A microfluidic device for label-free, physical capture of circulating tumor cell clusters. | Nat Methods | 2015 | https://conductscience.org/library/papers/25984697 | PubMed |
1 to 10 of 94
See all 94 referencesCited by213
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 278 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,958,405 | Deep N-glycoproteomic profiling of FFPE tissues enables precise diagnosis of primary liver cancer from metastatic liver cancer. | J Transl Med | 2026 | https://conductscience.org/library/papers/42958405 | PubMed |
| 42,947,149 | CTC-AttnNet: development and validation of an attention-based neural network for staging gastrointestinal malignancies. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42947149 | PubMed |
| 42,909,923 | Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic Resistance. | Liver Cancer | 2026 | https://conductscience.org/library/papers/42909923 | PubMed |
| 42,884,598 | Preoperative Zinc Deficiency as a Novel Prognostic Predictor for Postoperative Recurrence in Hepatocellular Carcinoma. | Nutrients | 2026 | https://conductscience.org/library/papers/42884598 | PubMed |
| 42,602,972 | A CTC/DTC-centered temporal framework of bone metastasis: From dissemination to dormancy and reactivation. | J Bone Oncol | 2026 | https://conductscience.org/library/papers/42602972 | PubMed |
| 42,591,545 | HOXD9 prioritization within developmental regulator-related genes suggests stage-adjusted prognostic relevance in hepatocellular carcinoma. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591545 | PubMed |
| 42,552,362 | AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42552362 | PubMed |
| 42,445,440 | The evolving landscape of early diagnosis for hepatocellular carcinoma: a bibliometric analysis of global research trends (2016-2026) based on WoSCC database. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42445440 | PubMed |
| 42,437,748 | Tumor heterogeneity: development, mechanisms, and therapeutic implications. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42437748 | PubMed |
| 42,394,181 | Chemical and Technological Aspects of Magnetic Particles for Cancer Liquid Biopsy Applications. | ChemistryOpen | 2026 | https://conductscience.org/library/papers/42394181 | PubMed |
1 to 10 of 213
See all 213 cited byGenes39
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE | 1,636 | PubTator's text mining | https://conductscience.org/library/genes/1636 | NCBI Gene |
| AFP | 174 | PubTator's text mining | https://conductscience.org/library/genes/174 | NCBI Gene |
| AHSG | 197 | PubTator's text mining | https://conductscience.org/library/genes/197 | NCBI Gene |
| AKT2 | 208 | PubTator's text mining | https://conductscience.org/library/genes/208 | NCBI Gene |
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| ANXA2 | 302 | PubTator's text mining | https://conductscience.org/library/genes/302 | NCBI Gene |
| APOH | 350 | PubTator's text mining | https://conductscience.org/library/genes/350 | NCBI Gene |
| ASGR1 | 432 | PubTator's text mining | https://conductscience.org/library/genes/432 | NCBI Gene |
| BCAT1 | 586 | PubTator's text mining | https://conductscience.org/library/genes/586 | NCBI Gene |
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
1 to 10 of 39
See all 39 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32017145
GET https://conductscience.org/api/papers/v1/32017145/references?page=2